Antidote for organophosphate insecticide poisoning: atropine and pralidoxime

被引:8
|
作者
Chung, Sung Phil [1 ]
Roh, Hyung-Keun [2 ]
机构
[1] Yonsei Univ, Coll Med, Dept Emergency Med, Seoul, South Korea
[2] Gachon Univ, Grad Sch Med, Div Clin Pharmacol, Dept Internal Med, Inchon, South Korea
来源
关键词
Organophosphate; Poisoning; Antidote; Atropine; Pralidoxime; PESTICIDE; INTOXICATION; PYRIDINE-2-ALDOXIME; PHARMACOKINETICS; MANAGEMENT; TOXICITY; INFUSION; THERAPY;
D O I
10.5124/jkma.2013.56.12.1057
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute organophosphate (OP) poisoning produces cholinergic symptoms resulting from the inhibition of cholinesterase, and the overstimulation of muscarinic and nicotinic receptors in the synapses. The dominant clinical features of acute cholinergic toxicity include bradycardia, miosis, lacrimation, salivation, bronchorrhea, and bronchospasm. All symptomatic patients should receive therapy with oxygen, atropine, and pralidoxime. Atropine works as a physiologic antidote by competitively occupying muscarinic receptor sites, reducing the effects of excessive acetylcholine. Atropine should be immediately administered, and the dose can be titrated according to the severity of OP poisoning. A large dose may be necessary to overcome the excessive cholinergic state in case of severe poisoning. Pralidoxime is a biochemical antidote that reactivates acetylcholinesterase by removing OP from it. It is effective in treating both muscarinic and nicotinic symptoms. After some period of time, the acetylcholinesterase-OP compound undergoes a conformational change, known as aging, which renders the enzyme irreversibly resistant to reactivation by a pralidoxime. There has been a great deal of controversy over the effectiveness of pralidoxime in acute OP poisoning. However, it may be beneficial to administer pralidoxime for a sufficient period in case of severe poisoning with a large quantity of OP, which is common in Korea.
引用
收藏
页码:1057 / 1066
页数:10
相关论文
共 50 条
  • [21] The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning
    Schexnayder, S
    James, LP
    Kearns, GL
    Farrar, HC
    JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1998, 36 (06): : 549 - 555
  • [22] Clinical study of continuous micropump infusion of atropine and pralidoxime chloride for treatment of severe acute organophosphorus insecticide poisoning
    Liu, Hong-Xiang
    Liu, Chang-Fang
    Yang, Wan-Hua
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2015, 78 (12) : 709 - 713
  • [23] ANTIDOTE TREATMENT OF PERCUTANEOUS ORGANOPHOSPHATE POISONING ON RATS
    OLDIGES, H
    ARZNEIMITTEL-FORSCHUNG, 1971, 21 (07): : 1028 - &
  • [24] ATROPINE IS NOT AN ANTIDOTE OF CHLORMEQUAT POISONING: ABOUT THE EVENT
    Nisse, P.
    Assez, N.
    Kahn, JPh
    Mathieu-Nolf, M.
    ACTA CLINICA BELGICA, 2013, 68 (06): : 468 - 468
  • [25] Respiratory failure in organophosphate insecticide poisoning
    Noshad, Hamid
    Ansarin, Khalil
    Ardalan, Mohammad R.
    Ghaffari, Ali R.
    Safa, Javid
    Nezami, Nariman
    SAUDI MEDICAL JOURNAL, 2007, 28 (03) : 405 - 407
  • [26] SUBACUTE POISONING WITH PHOSALONE, AN ORGANOPHOSPHATE INSECTICIDE
    OMALLEY, MA
    MCCURDY, SA
    WESTERN JOURNAL OF MEDICINE, 1990, 153 (06): : 619 - 624
  • [27] Stability study of a new antidote drug combination (Atropine-HI-6-Prodiazepam) for treatment of organophosphate poisoning
    Clair, P
    Wiberg, K
    Granelli, I
    Bratt, IC
    Blanchet, G
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 9 (03) : 259 - 263
  • [28] SUCCESSFUL USE OF AN ANTIDOTE IN PHOSPHORUS INSECTICIDE POISONING
    BENNETT, BG
    BEST, J
    MEDICAL JOURNAL OF AUSTRALIA, 1962, 2 (04) : 150 - &
  • [29] USE OF CONTINUOUS INFUSION OF PRALIDOXIME FOR TREATMENT OF ORGANOPHOSPHATE POISONING IN CHILDREN
    FARRAR, HC
    WELLS, TG
    KEARNS, GL
    JOURNAL OF PEDIATRICS, 1990, 116 (04): : 658 - 661
  • [30] PHARMACOKINETICS OF CONTINUOUS INFUSION PRALIDOXIME IN INFANTS AND CHILDREN WITH ORGANOPHOSPHATE POISONING
    SCHEXNAYDER, S
    KEARNS, G
    WELLS, T
    CLINICAL RESEARCH, 1991, 39 (04): : A832 - A832